13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001940272
Total reported value
$2.2B
$2.2B
250 檔
9.9%
At the close of Q2 2024, ADAR1 Capital Management, LLC disclosed equity holdings valued at approximately $2.2B, spread across 250 reported holdings.
During Q2 2024, ADAR1 Capital Management, LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
Showing top 200 holdings (of 250 total)
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 10.49% | -0.78% | +104.15% | |
| 2 | CYTK | Cytokinetics Inc | Stock-Healthcare | 8.73% | -0.66% | +165.20% | |
| 3 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 8.28% | -0.25% | +48.65% | |
| 4 | BOXX | Alpha Architect 1-3 Mnth Box | ETF-Other | 7.15% | -0.50% | +10.49% | |
| 5 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 6.07% | +0.19% | +130.39% | |
| 6 | RPRX | Royalty Pharma plc | Stock-Healthcare | 5.88% | +0.02% | +63.78% | |
| 7 | INSM | Insmed Inc | Stock-Healthcare | 4.97% | +0.78% | +23018.65% | |
| 8 | KROS | Keros Therapeutics Inc | Stock-Other | 4.74% | +0.06% | +62.28% | |
| 9 | IMVT | Immunovant Inc | Stock-Other | 2.38% | +0.19% | +684.27% | |
| 10 | ABUS | Arbutus Biopharma CORP | Stock-Other | 1.92% | -0.55% | +58.58% | |
| 11 | MRK | Merck & Co. Inc. | Stock-Healthcare | 1.77% | — | +25150.00% | |
| 12 | RZLT | Rezolute Inc | Stock-Other | 1.68% | — | — | |
| 13 | SLDB | Solid Biosciences Inc | Stock-Other | 1.52% | — | +599.01% | |
| 14 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 1.48% | +0.10% | +141.34% | |
| 15 | ✓ | Stock-Other | 1.42% | +0.02% | — | ||
| 16 | ASND | Ascendis Pharma A/S | Stock-Other | 1.32% | -0.34% | EXIT | |
| 17 | TECX | Tectonic Therapeutic Inc | Stock-Other | 1.11% | — | — | |
| 18 | CERE1EUR | Cerevel Therapeutics Holding | Stock-Other | 1.11% | — | +92.79% | |
| 19 | QURE | uniQure N.V. | Stock-Other | 1.03% | +0.51% | +317.51% | |
| 20 | ABSI | Absci CORP | Stock-Other | 0.99% | — | +189.37% | |
| 21 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 0.91% | +0.58% | +533.48% | |
| 22 | ALKS | Alkermes plc | Stock-Healthcare | 0.89% | -0.10% | EXIT | |
| 23 | SPY | Ss Spdr S&p 500 ETF Trust-us | ETF-Large Cap & Growth | 0.82% | +2.36% | -84.62% | |
| 24 | ✓ | Helix Acquisition CORP Ii | Stock-Other | 0.78% | — | +0.16% | |
| 25 | ANAB | Anaptysbio Inc | Stock-Other | 0.74% | — | +5143.30% | |
| 26 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 0.63% | -0.35% | — | |
| 27 | BIL | Ss Spdr Bb 1-3m T-bill ETF | ETF-Gov Bonds | 0.56% | -0.16% | — | |
| 28 | QTTB | Q32 Bio Inc | Stock-Other | 0.53% | -0.01% | EXIT | |
| 29 | ✓ | Stock-Other | 0.53% | — | +341.42% | ||
| 30 | SVRA | Savara Inc | Stock-Other | 0.52% | -0.07% | +12035.68% | |
| 31 | VUSB | Vanguard Ultra Short Bond Et | ETF-Other | 0.52% | — | — | |
| 32 | JPST | Jpmorgan Ultra-short Income | ETF-Other | 0.51% | — | — | |
| 33 | SHV | Ishares 0-1 Year Treasury Bo | ETF-Gov Bonds | 0.51% | — | — | |
| 34 | OABI | Omniab Inc | Stock-Other | 0.50% | +0.04% | +57.83% | |
| 35 | USFR | Wisdomtree Floating Rate Tre | ETF-Other | 0.50% | -0.01% | — | |
| 36 | ACHV | Achieve Life Sciences Inc | Stock-Other | 0.48% | +0.01% | -38.03% | |
| 37 | FULC | Fulcrum Therapeutics Inc | Stock-Other | 0.45% | +0.20% | +14.29% | |
| 38 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 0.43% | -0.09% | EXIT | |
| 39 | KALAEUR | Kala Bio Inc | Stock-Other | 0.41% | — | EXIT | |
| 40 | KNSA | Kiniksa Pharmaceuticals International, plc | Stock-Other | 0.40% | — | — | |
| 41 | ULST | Ss Ultra Short Tm Bond ETF | ETF-Other | 0.36% | — | — | |
| 42 | BEAM | Beam Therapeutics Inc | Stock-Other | 0.32% | -2.03% | EXIT | |
| 43 | CLRBUSD | Cellectar Biosciences Inc | Stock-Other | 0.32% | — | +6.16% | |
| 44 | TEVA | Teva Pharmaceutical-sp Adr | Stock-Healthcare | 0.32% | -0.05% | +1.47% | |
| 45 | DCTH | Delcath Systems Inc | Stock-Other | 0.31% | +0.01% | -9.42% | |
| 46 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 0.31% | -0.09% | EXIT | |
| 47 | APGE | Apogee Therapeutics Inc | Stock-Other | 0.30% | +0.19% | NEW | |
| 48 | ✓ | Merus N V | Stock-Other | 0.30% | — | — | |
| 49 | ONC | Beone Medicines Ltd-adr | Stock-Other | 0.30% | -0.05% | -64.77% | |
| 50 | AURA | Aura Biosciences Inc | Stock-Other | 0.29% | +0.04% | NEW |
According to official SEC Form 13F filings, ADAR1 Capital Management, LLC reported a total U.S. public equity portfolio value of $2.2B across 250 disclosed positions in Q2 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including PTGX, CYTK, ROIV) accounted for 9.9% of total reported equity market value during Q2 2024.
During Q2 2024, ADAR1 Capital Management, LLC's top holdings by market value included PTGX (10.5%)、CYTK (8.7%)、ROIV (8.3%). The largest single position, PTGX, represented 10.5% of total portfolio value.
In Q2 2024, ADAR1 Capital Management, LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.